Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13010704 | 0.98 | KDM4E (0.40) | KDM4ESMN1; SMN2HSD11B1OPRM1OPRL1 | |
| SCHEMBL27346203 | 0.93 | KDM4E (0.40) | KDM4ESMN1; SMN2HSD11B1OPRM1OPRL1 | |
| SCHEMBL824152 | 0.88 | SMN1; SMN2 (0.45) | KDM4ESMN1; SMN2HSD11B1OPRM1OPRL1 | |
| SCHEMBL13542421 | 0.87 | CYP3A4 (0.36) | KDM4ECYP2D6CYP1A2CYP3A4 | |
| SCHEMBL15292513 | 0.87 | CYP3A4 (0.36) | KDM4ECYP2D6CYP1A2CYP3A4 | |
| SCHEMBL1615683 | 0.87 | CYP3A4 (0.36) | KDM4ECYP2D6CYP1A2CYP3A4 | |
| SCHEMBL23965559 | 0.81 | SMN1; SMN2 (0.41) | KDM4ESMN1; SMN2HSD11B1CYP2D6KMT2A | |
| SCHEMBL14543763 | 0.81 | SHBG (0.35) | KDM4EHSD11B1OPRM1OPRL1CYP2D6 | |
| SCHEMBL14519150 | 0.81 | DRD2 (0.41) | SMN1; SMN2 | |
| SCHEMBL14519155 | 0.81 | SHBG (0.35) | KDM4EHSD11B1OPRM1OPRL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | BIAL R&D INVEST S A (PT) | 2022-12-22 | — | — | US | disclosed |
| US-9725442-B2 | Heterocyclic derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD. (JP) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | ASAH2, ASAH1, GBA1 | KDM4E 2033/4885SMN1; SMN2 306/4885HSD11B1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.